FIG Invests in Elitepharm to Integrate AI in Nutraceuticals
Freedom International Group (FIG) has announced a strategic investment in Elitepharm Laboratoires, as stated in a press release. This move positions FIG as a major shareholder in Elitepharm, a leading French company specializing in the formulation and production of dietary supplements.
The investment aims to leverage AI technology to improve the efficiency and effectiveness of dietary supplement production. Narek Sirakanyan, President and CEO of FIG, highlighted the strategic importance of this investment, noting that France's regulatory environment and technological advancements make it an ideal location for producing dietary supplements.
Elitepharm plans to use this investment to accelerate its commercial and industrial development. The company intends to strengthen its existing facilities, acquire new production sites, and expand its private label portfolio. This expansion is part of a broader strategy to enhance control over the value chain and ensure high-quality production standards.
The partnership between FIG and Elitepharm is based on a shared vision of innovation and industrial excellence, with the goal of establishing Elitepharm as a major player in the European market by 2029.
We hope you enjoyed this article.
Consider subscribing to one of several newsletters we publish like Life AI Weekly.
Also, consider following us on social media:
More from: Healthcare & Life Sciences
Genesis Therapeutics Appoints Aleksandra Faust as Chief AI Officer
Ellipsis Health Unveils AI Care Manager Sage with $45M Funding
Deep Apple and Novo Nordisk Partner on Cardiometabolic Drug Discovery
Outcomes4Me Acquires Mika Health App to Enhance AI-Driven Cancer Care
More from: Funding
Scale AI Receives Major Investment from Meta, CEO Transition Announced
Sunrise Robotics Secures $8.5M to Enhance European Manufacturing
Google Ends $200M Deal with Scale AI After Meta's Investment
Nominal Secures $75 Million to Revolutionize Hardware Testing
TELUS Proposes Full Acquisition of TELUS Digital
Subscribe to Life AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Whitepaper
Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation
The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.
Read more